PROCEPT BioRobotics Corporation
PRCT
Positions held
Your positionsPRCT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- PROCEPT BioRobotics operates in the growing medical devices sector, focusing on innovative solutions for urological conditions, which positions it well against competitors.
- Revenue increased by 14% compared to the prior quarter, reaching $94 million.
- Gross margin improved to 66%, up from 64.9% in the previous quarter.
- The company has a negative profit margin of -32.54%, indicating ongoing financial challenges.
- Operating margin remains negative at -29%, reflecting continued operational losses.
- The stock has a 'Strong Sell' signal with a score of -24.00, indicating bearish market sentiment.
Fundamentals
| Market cap | $1.02B | Enterprise value | $874.78M | Trailing P/E | — | Forward P/E | -15.26 |
| PEG | — | Price / book | 3.01 | Beta | 0.92 | Dividend yield | 0.00% |
| Revenue growth | 19.3% | Earnings growth | — | Gross margin | 63.4% | Operating margin | -32.1% |
| Profit margin | -32.5% | ROE | -30.2% | ROA | -14.8% | Debt / equity | 0.23 |
| Current ratio | 6.55 | Free cash flow | -$48.97M | Analyst recommendation | hold | Mean target | $22.42 |
| 52w high | $38.11 | 52w low | $16.67 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $94.5M | $83.1M | $76.4M | $83.3M | $79.2M | — |
| Op margin | -29.0% | -39.2% | -40.6% | -27.8% | -28.0% | — |
| Net income | -$26.9M | -$31.6M | -$29.8M | -$21.4M | -$19.6M | — |
| Gross margin | 66.0% | 64.9% | 60.6% | 64.8% | 65.4% | — |
| Gross profit | $62.4M | $53.9M | $46.3M | $54.0M | $51.7M | — |
| Operating income | -$27.4M | -$32.6M | -$31.0M | -$23.2M | -$22.2M | — |
- Revenue +14% vs prior quarter ($94M vs $83M).
- Gross margin 66% (was 64.9% prior quarter).
- Operating margin expanded to -29%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $308M | $224M | $136M | $75.0M | — |
| Op margin | -33.7% | -43.0% | -80.2% | -107.6% | — |
| Net income | -$95.6M | -$91.4M | -$106M | -$87.2M | — |
| Gross margin | 63.7% | 61.1% | 52.2% | 49.4% | — |
| Gross profit | $196M | $137M | $71.0M | $37.1M | — |
| Operating income | -$104M | -$96.6M | -$109M | -$80.7M | — |
Headlines — watch
• [WARN · legal] Does New Director and Discounting Lawsuit Change The Bull Case For PROCEPT BioRobotics (PRCT)?
• [WARN · legal] PROCEPT BioRobotics (PRCT) Could Be 70% Undervalued On Lawsuit And Board Change
News
2026-10-08 · PROCEPT BioRobotics (PRCT) Could Be 70% Undervalued On Lawsuit And Board Change
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-07 · Barclays Initiates PROCEPT BioRobotics at Overweight With $30 Price Target
2026-10-06 · Does New Director and Discounting Lawsuit Change The Bull Case For PROCEPT BioRobotics (PRCT)?
2026-09-22 · THINK Surgical Appoints Rick McDowell as Vice President, Sales
2026-08-18 · Procept BioRobotics CEO Buys 23,900 Shares Amid 48% Stock Decline. What Does This Tell Investors?
2026-08-17 · PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026
2026-08-11 · PROCEPT BioRobotics (PRCT) Q2 2026 Earnings Call Transcript
2026-08-10 · Procept Biorobotics Insider Bought Shares Worth $498,315, According to a Recent SEC Filing
2026-08-08 · PROCEPT BioRobotics (PRCT) Stock Sees Fair Value Falls As Analysts Cut Growth Views
2026-08-05 · PROCEPT BioRobotics Corporation Q2 2026 Earnings Call Summary
2026-08-05 · Truist Adjusts Price Target on PROCEPT BioRobotics to $21 From $26, Maintains Hold Rating
Price (daily)
Full chart · RSI · MACD · patterns